...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies >The use of enteral naloxone to treat opioid-induced constipation in a pediatric intensive care unit.
【24h】

The use of enteral naloxone to treat opioid-induced constipation in a pediatric intensive care unit.

机译：在儿科重症监护病房使用肠纳洛酮治疗阿片类药物引起的便秘。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To describe the effects of enteral naloxone used to treat opioid-induced constipation in pediatric intensive care patients. DESIGN: Retrospective chart review. SETTING: Pediatric intensive care unit. PATIENTS: Twenty-three patients who received opioid therapy and enteral naloxone in our institution from January 2003 to February 2004 were compared with a randomly sampled control group matched for age, weight, sex, and length of stay who received opioids but had not received enteral naloxone. INTERVENTIONS: None. MEASUREMENTS: Daily stool output, daily opiate usage, nutrition, adjuvant laxative use, and side effects were assessed. RESULTS: Patients stayed an average of 5 days (range, 0-13 days) in the pediatric intensive care unit before enteral administration of naloxone was instituted and received it for an average of 9 consecutive days (range, 3-30 days). Mean stool output for study patients before administration of enteral naloxone was 0.14 +/- 0.38 stools per day, whereas after its initiation it was 1.60 +/- 1.14 stools per day (p < .001). However, two patients developed significant opiate withdrawal symptoms after receiving enteral naloxone. The average stool output for control patients was 0.53 +/- 1.21 stools per day. CONCLUSIONS: Enteral naloxone may be effective in increasing stool output in opioid-induced constipation but carries the risk of introducing withdrawal symptoms. Further studies are needed to evaluate this agent for opioid-induced constipation in the intensive care unit.
机译：目的：描述肠纳洛酮在小儿重症监护患者中治疗阿片类药物引起的便秘的作用。设计：回顾性图表审查。地点：儿科重症监护室。患者：2003年1月至2004年2月在我们机构接受阿片类药物治疗和肠内纳洛酮的23例患者与年龄，体重，性别和住院时间相匹配的随机抽样对照组进行比较，这些对照组接受了阿片类药物但未接受肠内治疗纳洛酮。干预措施：无。测量：评估每日排便量，每日鸦片使用量，营养，辅助性泻药使用和副作用。结果：在开始肠内给予纳洛酮治疗之前，患者在小儿重症监护室平均停留5天（范围0-13天），并平均连续接受9天（范围3-30天）。在服用肠纳洛酮之前，研究患者的平均粪便产量为每天0.14 +/- 0.38粪便，而开始服用后为每天1.60 +/- 1.14粪便（p <.001）。然而，两名患者在接受肠纳洛酮后出现了明显的鸦片戒断症状。对照患者的平均大便排出量为每天0.53 +/- 1.21个大便。结论：肠纳洛酮可能有效增加阿片类药物引起的便秘的粪便量，但存在引入戒断症状的风险。需要进一步研究以评估这种药物在重症监护病房中对阿片类药物引起的便秘的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号